These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29808308)

  • 1. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
    Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
    Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
    O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.
    Bahleda R; Varga A; Bergé Y; Soria JC; Schnell D; Tschoepe I; Uttenreuther-Fischer M; Delord JP
    Br J Cancer; 2018 Feb; 118(3):344-352. PubMed ID: 29337963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
    Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
    Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
    Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E
    Eur J Cancer; 2018 Nov; 104():1-8. PubMed ID: 30278378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
    Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
    Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
    Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
    Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
    Marshall J; Shapiro GI; Uttenreuther-Fischer M; Ould-Kaci M; Stopfer P; Gordon MS
    Future Oncol; 2013 Feb; 9(2):271-81. PubMed ID: 23414476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
    Salazar R; Morales S; Gil-Martín M; Aguirre E; Oaknin A; Garcia M; Callies S; Wickremsinhe ER; Benhadji KA; Llombart A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1205-15. PubMed ID: 24744161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
    Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
    Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
    Vermorken JB; Rottey S; Ehrnrooth E; Pelling K; Lahogue A; Wind S; Machiels JP
    Ann Oncol; 2013 May; 24(5):1392-400. PubMed ID: 23293114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
    Raymond E; Alexandre J; Faivre S; Goldwasser F; Besse-Hammer T; Gianella-Borradori A; Jego V; Trandafir L; Rejeb N; Awada A
    Invest New Drugs; 2014 Feb; 32(1):94-103. PubMed ID: 23539344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.